These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38084551)

  • 41. CBFB-MYH11 Fusion Sequesters RUNX1 in Cytoplasm to Prevent DNMT3A Recruitment to Target Genes in AML.
    Liu P; Liu JP; Sun SJ; Gao Y; Ai Y; Chen X; Sun Y; Zhou M; Liu Y; Xiong Y; Yuan HX
    Front Cell Dev Biol; 2021; 9():675424. PubMed ID: 34336831
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia.
    Pedersen-Bjergaard J; Pedersen M; Roulston D; Philip P
    Blood; 1995 Nov; 86(9):3542-52. PubMed ID: 7579462
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognosis and therapy when acute promyelocytic leukemia and other "good risk" acute myeloid leukemias occur as a therapy-related myeloid neoplasm.
    Larson RA; Le Beau MM
    Mediterr J Hematol Infect Dis; 2011; 3(1):e2011032. PubMed ID: 21869918
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Therapy-related core binding factor acute myeloid leukemia.
    George B; Yohannan B; Mohlere V; Gonzalez A
    Int J Hematol Oncol; 2023 Feb; 12(1):IJH43. PubMed ID: 36874378
    [TBL] [Abstract][Full Text] [Related]  

  • 45. miR-17 deregulates a core RUNX1-miRNA mechanism of CBF acute myeloid leukemia.
    Fischer J; Rossetti S; Datta A; Eng K; Beghini A; Sacchi N
    Mol Cancer; 2015 Jan; 14():7. PubMed ID: 25612891
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Autonomous feedback loop of RUNX1-p53-CBFB in acute myeloid leukemia cells.
    Morita K; Noura M; Tokushige C; Maeda S; Kiyose H; Kashiwazaki G; Taniguchi J; Bando T; Yoshida K; Ozaki T; Matsuo H; Ogawa S; Liu PP; Nakahata T; Sugiyama H; Adachi S; Kamikubo Y
    Sci Rep; 2017 Nov; 7(1):16604. PubMed ID: 29192243
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes.
    Yalniz FF; Patel KP; Bashir Q; Marin D; Ahmed S; Alousi AM; Chen J; Ciurea SO; Rezvani K; Popat UR; Shpall EJ; Champlin RE; Oran B
    Cancer; 2020 May; 126(10):2183-2192. PubMed ID: 32101640
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Downregulation of RUNX1/CBFβ by MLL fusion proteins enhances hematopoietic stem cell self-renewal.
    Zhao X; Chen A; Yan X; Zhang Y; He F; Hayashi Y; Dong Y; Rao Y; Li B; Conway RM; Maiques-Diaz A; Elf SE; Huang N; Zuber J; Xiao Z; Tse W; Tenen DG; Wang Q; Chen W; Mulloy JC; Nimer SD; Huang G
    Blood; 2014 Mar; 123(11):1729-38. PubMed ID: 24449215
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Therapy-related acute lymphoblastic leukaemia with MLL rearrangements following DNA topoisomerase II inhibitors, an increasing problem: report on two new cases and review of the literature since 1992.
    Andersen MK; Christiansen DH; Jensen BA; Ernst P; Hauge G; Pedersen-Bjergaard J
    Br J Haematol; 2001 Sep; 114(3):539-43. PubMed ID: 11552977
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias.
    Ommen HB; Schnittger S; Jovanovic JV; Ommen IB; Hasle H; Østergaard M; Grimwade D; Hokland P
    Blood; 2010 Jan; 115(2):198-205. PubMed ID: 19901261
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Truncated RUNX1 Generated by the Fusion of RUNX1 to Antisense GRIK2 via a Cryptic Chromosome Translocation Enhances Sensitivity to Granulocyte Colony-Stimulating Factor.
    Abe A; Yamamoto Y; Katsumi A; Yamamoto H; Okamoto A; Inaguma Y; Iriyama C; Tokuda M; Okamoto M; Emi N; Tomita A
    Cytogenet Genome Res; 2020; 160(5):255-263. PubMed ID: 32544910
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Distribution of 11q23 breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment-related acute myeloid leukemia: correlation with scaffold attachment regions and topoisomerase II consensus binding sites.
    Broeker PL; Super HG; Thirman MJ; Pomykala H; Yonebayashi Y; Tanabe S; Zeleznik-Le N; Rowley JD
    Blood; 1996 Mar; 87(5):1912-22. PubMed ID: 8634439
    [TBL] [Abstract][Full Text] [Related]  

  • 53. All patients with the T(11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders.
    Rowley JD; Reshmi S; Sobulo O; Musvee T; Anastasi J; Raimondi S; Schneider NR; Barredo JC; Cantu ES; Schlegelberger B; Behm F; Doggett NA; Borrow J; Zeleznik-Le N
    Blood; 1997 Jul; 90(2):535-41. PubMed ID: 9226152
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CBFB-MYH11 hinders early T-cell development and induces massive cell death in the thymus.
    Zhao L; Cannons JL; Anderson S; Kirby M; Xu L; Castilla LH; Schwartzberg PL; Bosselut R; Liu PP
    Blood; 2007 Apr; 109(8):3432-40. PubMed ID: 17185462
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Runx1 is required for hematopoietic defects and leukemogenesis in Cbfb-MYH11 knock-in mice.
    Hyde RK; Zhao L; Alemu L; Liu PP
    Leukemia; 2015 Aug; 29(8):1771-8. PubMed ID: 25742748
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bundles of Auer rods in maturing myeloid cells in a case of acute myeloid leukaemia with CBFB::MYH11 rearrangement and concomitant KIT mutation.
    Li THS; Lau WP; Ng KY; Wong WS
    Pathology; 2024 Apr; 56(3):455-457. PubMed ID: 37923609
    [No Abstract]   [Full Text] [Related]  

  • 57. Translocation (4;11)(p12;q23) with rearrangement of FRYL and MLL in therapy-related acute myeloid leukemia.
    Sait SN; Claydon MA; Conroy JM; Nowak NJ; Barcos M; Baer MR
    Cancer Genet Cytogenet; 2007 Sep; 177(2):143-6. PubMed ID: 17854671
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Detection of del(16q) using the CBFB-MYH11 translocation dual fusion probe.
    Temerik DF; El-Mahdy WT; Ahmed AM
    Hematol Oncol Stem Cell Ther; 2021 Dec; 14(4):351-352. PubMed ID: 32202250
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease.
    Hoyos M; Nomdedeu JF; Esteve J; Duarte R; Ribera JM; Llorente A; Escoda L; Bueno J; Tormo M; Gallardo D; de Llano MPQ; Martí JM; Aventín A; Mangues R; Brunet S; Sierra J
    Eur J Haematol; 2013 Sep; 91(3):209-218. PubMed ID: 23646898
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CBFB-MYH11/RUNX1 together with a compendium of hematopoietic regulators, chromatin modifiers and basal transcription factors occupies self-renewal genes in inv(16) acute myeloid leukemia.
    Mandoli A; Singh AA; Jansen PW; Wierenga AT; Riahi H; Franci G; Prange K; Saeed S; Vellenga E; Vermeulen M; Stunnenberg HG; Martens JH
    Leukemia; 2014 Apr; 28(4):770-8. PubMed ID: 24002588
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.